Louise Bordeleau - McMaster Experts

Affiliations

Faculty of Health Sciences, McMaster University
Oncology (Internal), Faculty of Health Sciences
Associate Member, Health Research Methods, Evidence, and Impact, Faculty of Health Sciences
Associate Professor, Oncology, Faculty of Health Sciences

Scholarly Activity in McMaster Experts

Co-author Network

Scholarly Activity
Contact
View All

selected scholarly activity

chapters
- Medical, Psychosocial, and Health-Related Quality of Life Issues in Breast Cancer Survivors. 122-144. 2007
- Medical, Psychosocial, and Health-Related Quality of Life Issues in Breast Cancer Survivors. 1846-1868. 2006
conferences
- eP160: Bilateral oophorectomy and the risk of breast cancer in women with a pathogenic variant in BRCA1: A reappraisal. Genetics in Medicine. S98-S98. 2022
- Development and Psychometric Validation of BREAST-Q Scales Measuring Cancer Worry, Fatigue, and Impact on Work. Annals of Surgical Oncology. 7410-7420. 2021
- Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology, Biomarkers and Prevention. 2038-2043. 2021
- Development of LYMPH-Q upper extremity scales measuring worry, work impact, and burden of conservative treatments. Quality of Life Research. S91-S91. 2021
- Contraceptive use and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers: A prospective cohort study.. Cancer Research. 2021
- Examining content validity of BREAST-Q a decade later to determine relevance and comprehensiveness. Quality of Life Research. S75-S75. 2019
- Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693). Cancer Research. 2019
- Assessment of myocardial injury early after initiation of treatment in breast cancer patients using the Beckman Coulter and Abbott Diagnostics high-sensitivity cardiac troponin I tests. Clinical Biochemistry. 56-57. 2018
- Development of health-state classification system for a new breast cancer-specific preference-based measure: the BREAST-Q-U. Quality of Life Research. S18-S19. 2018
- Abstract P5-20-17: Safety of continuing chemotherapy in overt left ventricular dysfunction using antibodies to human epidermal growth factor receptor-2: A retrospective study. Cancer Research. p5-20-17-p5-20-17. 2018
- Safety of continuing chemotherapy in overt left ventricular dysfunction using antibodies to human epidermal growth factor receptor-2: A retrospective study. Cancer Research. 2018
- NCI Breast Cancer Steering Committee Working Group (WG) report on meaningful and appropriate endpoints for clinical trials (CT) in metastatic breast cancer (MBC).. Journal of Clinical Oncology. 1073-1073. 2017
- The feasibility, acceptability and safety of Molecular Breast Imaging (MBI) using a breast specific gamma camera and 99mTc-sestamibi in patients with a high risk of breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. S462-S462. 2013
- Cancer Outcomes in Patients With Dysglycemia on Basal Insulin: Results of the ORIGIN Trial. Diabetes. A98-A98. 2013
- Cancer Outcomes in Patients With Dysglycemia on Basal Insulin: Results of the ORIGIN Trial. Diabetes. A72-A72. 2013
- A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer.. Journal of Clinical Oncology. 9020-9020. 2011
- Incident cancers in people with dysglycemia and other cardiovascular risk factors: Cohort study of the ORIGIN trial.. Journal of Clinical Oncology. 1504-1504. 2011
- Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919).. Journal of Clinical Oncology. TPS108-TPS108. 2011
- Absence of Histologic Differences between Benign Breast Tissue from BRCA Carriers and Controls Despite Differential Gene Expression. Modern Pathology. 39A-39A. 2011
- Absence of Histologic Differences between Benign Breast Tissue from BRCA Carriers and Controls Despite Differential Gene Expression. Laboratory Investigation. 39A-39A. 2011
- Abstract P2-11-01: Molecular Profiling Identifies Differentially Expressed Genes between Normal Breast Tissue from BRCA Carriers and Women at Population Risk. Cancer Research. 2010
- A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors.. Journal of Clinical Oncology. 9023-9023. 2010
- Willingness of breast cancer survivors to participate in a randomized controlled trial (RCT) of digital mammography with or without magnetic resonance imaging (MRI) as breast cancer (BC) surveillance: A feasiblity study. Journal of Clinical Oncology. 2009
- Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.. Anticancer Research. 1557-1562. 2009
- A comparison of internet-based models assessing the likelihood of a BRCA mutation. Journal of Clinical Oncology. 22051-22051. 2008
- Health preference instruments in a breast cancer population: Is there a ceiling effect when compared to the quality-of-life instruments?. Journal of Clinical Oncology. 6597-6597. 2008
- Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status with time: Discordance rates between primary and metastatic breast pathology samples. Journal of Clinical Oncology. 2007
- Descriptive study on the lost productivity in breast cancer patients. Journal of Clinical Oncology. 2007
- Identification of cancer care and protocol characteristics associated with recruitment rate in breast cancer clinical trials in Ontario. Journal of Clinical Oncology. 2007
- A comparison of BRCA1 and BRCA2 risk assessment models.. Journal of Clinical Oncology. 549S-549S. 2006
- Evaluating the performance of risk assessment models in BRCA1 and BRCA2 mutation detection.. Breast Cancer Research and Treatment. S179-S179. 2006
- Evaluation of responsiveness to change to psychosocial group therapy (PGT) and to the process of dying of psychosocial and quality of life (QOL) measures.. Journal of Clinical Oncology. 737S-737S. 2005
- Health related quality of life (HRQOL) and psychosocial status at diagnosis are not associated with disease-free or overall survival (DFS or OS) in T1-3, N0-1, M0 breast cancer (BC).. Breast Cancer Research and Treatment. S43-S43. 2002
- 5-Aza-2 '-deoxycytidine (5-Aza-2-Cdr) reverses CpG methylation of the retinoic acid receptor beta (RAR beta) promoter and restores retinoid responsiveness in non M3 acute myelogenous leukemia (AML) blasts.. Blood. 460A-460A. 2001
- Phase II study of repetitive mini-transplant using a novel dose-intense salvage chemotherapy regimen (M-DHAP) followed by high dose therapy (HDT) and autologous stem cell transplant (ASCT) in relapsed aggressive non-Hodgkin lymphoma (NHL).. Blood. 390B-390B. 2001
- Molecular diagnostics in follicular non-Hodgkin's lymphoma: A review. Seminars in Oncology. 42-52. 2000
- Decreased bone mineral density after autologous blood and marrow transplantation(ABMT).. Blood. 342A-342A. 1999
- In vivo purging with rituxan prior to stem cell collection is associated with persistant molecular evidence of T(14;18) that often disappears post transplant in patients with follicular lymphoma.. Blood. 355B-355B. 1999
- Low-grade lymphoma: A prospective multicenter evaluation of clinical and biologic prognostic factors.. Blood. 242B-243B. 1999
- Outpatient autologous hematopoietic stem cell (HSCT) transplantation following short course VAD in multiple myeloma.. Blood. 373B-373B. 1998
- Incremental cost effectiveness of maintaining dose intensity with G-CSF as primary therapy of intermediate grade non-Hodgkin's lymphoma.. Blood. 848-848. 1997
journal articles
- The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation.. Cancer. 2024
- Incidence of endometrial cancer in BRCA mutation carriers.. Gynecologic Oncology. 189:148-155. 2024
- LBA37 Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN). Annals of Oncology. 35:s1228. 2024
- Iterative qualitative approach to establishing content validation of a patient-reported outcome measure for arm lymphedema: the LYMPH-Q Upper Extremity Module. Journal of Patient-Reported Outcomes. 8:63. 2024
- The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations. Hereditary Cancer in Clinical Practice. 22:7. 2024
- Acute Toxicity Results from the Randomized Assessment of Cisplatin Dosing Interval for Ototoxicity (RADIO) Trial Comparing Chemoradiation (CRT) with Cisplatin Q3weekly to Weekly for Locally Advanced Squamous Cell Carcinoma of the Head and neck (LASCCHN). International Journal of Radiation Oncology Biology Physics. 118:e9-e9. 2024
- Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncology. 10:484-484. 2024
- MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncology. 10:493-493. 2024
- Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. British Journal of Cancer. 130:269-274. 2024
- Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation. Cancer Research Communications. 3:2420-2429. 2023
- Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab. Oncologist. 28:e712-e722. 2023
- Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Research and Treatment. 201:257-264. 2023
- Detection of Macrotroponin in Patients Receiving Treatment for Breast Cancer. CJC OPEN. 5:658-660. 2023
- Re-examining content validity of the BREAST-Q more than a decade later to determine relevance and comprehensiveness. Journal of Patient-Reported Outcomes. 7:37. 2023
- The risks of cancer in older women with BRCA pathogenic variants: How far have we come?. Cancer. 129:901-907. 2023
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of Oncology. 33:1250-1268. 2022
- A Systematic Literature Review of Health Utility Values in Breast Cancer. Medical decision making. 42:704-719. 2022
- Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiology, Biomarkers and Prevention. 31:1351-1358. 2022
- Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology. 164:514-521. 2022
- The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele BRCA2 6174delT. Clinical Genetics. 101:317-323. 2022
- Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial. The BMJ. 375:e066588-e066588. 2021
- ASO Visual Abstract: Development and Psychometric Validation of BREAST-Q Scales Measuring Cancer Worry, Fatigue, and Impact on Work. Annals of Surgical Oncology. 28:453-454. 2021
- An international mixed methods study to develop a new preference-based measure for women with breast cancer: the BREAST-Q Utility module. BMC Women's Health. 21:8. 2021
- Development and Psychometric Validation of the BREAST-Q Sensation Module for Women Undergoing Post-Mastectomy Breast Reconstruction. Annals of Surgical Oncology. 28:7842-7853. 2021
- An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool. Cancer. 127:3183-3193. 2021
- Development and Psychometric Validation of the BREAST-Q Animation Deformity Scale for Women Undergoing an Implant-Based Breast Reconstruction After Mastectomy. Annals of Surgical Oncology. 28:5183-5193. 2021
- Abstract 878: Contraceptive use and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Cancer Research. 81:878-878. 2021
- Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 187:515-523. 2021
- Weight gain and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Molecular Genetics and Metabolism. 132:S357-S358. 2021
- Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology. 159:820-826. 2020
- Evaluation of a novel strategy to implement exercise evidence into clinical practice in breast cancer care: protocol for the NEXT-BRCA randomised controlled trial. BMJ Open Sport and Exercise Medicine. 6:e000922-e000922. 2020
- Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-Analyses. Oncology Nursing Forum. 47:E86-E106. 2020
- CanPROS Scientific Conference 2019 Oral Abstracts. Current Oncology. 27:57-63. 2020
- International phase 1 study protocol to develop a health state classification system for a preference-based measure for women with breast cancer: the BREAST-Q Utility module. BMJ Open. 10:e034451-e034451. 2020
- A post-hoc subgroup analysis assessing acute cardiac biomarker profiles in female cancer patients during adjuvant therapy. Clinica Chimica Acta. 495:355-357. 2019
- International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. British Journal of Cancer. 121:15-21. 2019
- Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 175:443-449. 2019
- Longitudinal High-Sensitivity Cardiac Troponin I Measurements in Patients With Breast Cancer Receiving Trastuzumab. Canadian Journal of Cardiology. 35:545.e1-545.e2. 2019
- National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. Journal of Clinical Oncology. 36:3259-3268. 2018
- Cancer prevention and screening in a BRCA2-positive male to female transgender patient. Breast Journal. 24:1112-1113. 2018
- Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncology. 4:1059-1059. 2018
- The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer. 142:2263-2272. 2018
- Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care. 39:709-716. 2016
- The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. British Journal of Cancer. 114:1160-1164. 2016
- Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. Journal of Clinical Oncology. 34:1065-1071. 2016
- Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility and Sterility. 105:781-785. 2016
- Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses. Systematic Reviews. 4:114. 2015
- Response to Suissa and Azoulay. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366. Diabetes Care. 37:e217-e217. 2014
- Response to Zanders et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366. Diabetes Care. 37:e223-e223. 2014
- Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 146:421-427. 2014
- The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care. 37:1360-1366. 2014
- Adjuvant Chemotherapy for Breast Cancer in a Patient with Primary Autoimmune Neutropenia. Breast Cancer: Basic and Clinical Research. 7:BCBCR.S10767-BCBCR.S10767. 2013
- Development and validation of a brief screening instrument for psychosocial risk associated with genetic testing: a pan-Canadian cohort study. BMJ Open. 3:e002227-e002227. 2013
- A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment. 136:143-151. 2012
- Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine. 367:319-328. 2012
- n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine. 367:309-318. 2012
- A fatal case of Pneumocystis jirovecii pneumonia in a breast cancer patient receiving weekly paclitaxel and trastuzumab. Journal of Oncology Pharmacy Practice. 18:293-295. 2012
- Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients. Journal of Oncology Pharmacy Practice. 18:311-315. 2012
- Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research. 14:R42. 2012
- Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. The Lancet Oncology. 13:275-284. 2012
- Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer. 117:1812-1818. 2011
- Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer: An Updated Systematic Review (2001–2009). Journal of the National Cancer Institute. 103:178-231. 2011
- Willingness of breast cancer survivors to participate in a randomized controlled trial of digital mammography with or without MRI as breast cancer surveillance: A feasibility study. Breast. 20:96-98. 2011
- Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors. Journal of Clinical Oncology. 28:5147-5152. 2010
- Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation‐positive families?. Clinical Genetics. 77:273-279. 2010
- Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Research and Treatment. 119:13-24. 2010
- Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer. Nature Reviews Clinical Oncology. 6:604-607. 2009
- Willingness of breast cancer survivors to participate in a randomized controlled trial (RCT) of digital mammography with or without magnetic resonance imaging (MRI) as breast cancer (BC) surveillance: A feasiblity study. Journal of Clinical Oncology. 27:1534-1534. 2009
- Selecting a BRCA risk assessment model for use in a familial cancer clinic. BMC Medical Genetics. 9:116. 2008
- Identification of Cancer Care and Protocol Characteristics Associated With Recruitment in Breast Cancer Clinical Trials. Journal of Clinical Oncology. 26:4458-4465. 2008
- Treating dural metastases mimicking intracranial hypotension.. The Journal of Supportive Oncology. 5:423-424. 2007
- Responsiveness to change due to supportive-expressive group therapy, improvement in mood and disease progression in women with metastatic breast cancer. Quality of Life Research. 16:1451-1451. 2007
- Responsiveness to change to change due to supportive-expressive group therapy, improvement in mood and disease progression in women with metastatic breast cancer. Quality of Life Research. 16:1007-1017. 2007
- Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status with time: Discordance rates between primary and metastatic breast pathology samples. Journal of Clinical Oncology. 25:1024-1024. 2007
- Descriptive study on the lost productivity in breast cancer patients. Journal of Clinical Oncology. 25:6542-6542. 2007
- Identification of cancer care and protocol characteristics associated with recruitment rate in breast cancer clinical trials in Ontario. Journal of Clinical Oncology. 25:17042-17042. 2007
- Three methods for minimally important difference: no relationship was found with the net proportion of patients improving. Journal of Clinical Epidemiology. 60:448-455. 2007
- Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review. Clinical Therapeutics. 29:230-241. 2007
- Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review.. Clinical Therapeutics. 29:230-241. 2007
- Management of the BRCA Mutation Carrier or High-Risk Patient. Clinics in Plastic Surgery. 34:15-27. 2007
- A comparison of BRCA1 and BRCA2 risk assessment models. Journal of Clinical Oncology. 24:10034-10034. 2006
- Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG). Annals of Oncology. 17:952-956. 2006
- Pharmacoeconomics of Systemic Therapies for Lung Cancer. Treatments in Respiratory Medicine. 5:129-141. 2006
- The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia. 19:1161-1168. 2005
- Evaluation of responsiveness to change to psychosocial group therapy (PGT) and to the process of dying of psychosocial and quality of life (QOL) measures. Journal of Clinical Oncology. 23:8035-8035. 2005
- Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables. Journal of Clinical Oncology. 22:4184-4192. 2004
- Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data. Journal of Clinical Oncology. 21:1944-1951. 2003
- Clinical manifestations associated with the aberrant expression of the soluble granulocyte–macrophage colony‐stimulating factor receptor in patients presenting with haematological malignancies. British Journal of Haematology. 121:86-93. 2003
- Review: breastfeeding is associated with reduced risk of breast cancer. BMJ Evidence-Based Medicine. 8:63-63. 2003
- Health-Related Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer--Taking Stock. Journal of the National Cancer Institute. 95:263-281. 2003
- Decreased bone mineral density is common after autologous blood or marrow transplantation. Bone Marrow Transplantation. 28:387-391. 2001
- A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis. Cancer. 92:23-29. 2001
- Molecular diagnostics in follicular non-Hodgkin's lymphoma: a review.. Seminars in Oncology. 27:42-52. 2000
- Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute. 92:1321-1329. 2000
- Economic Issues in Lung Cancer. Seminars in Respiratory and Critical Care Medicine. Volume 21:375-384. 2000
- Economic issues in lung cancer. Seminars in Respiratory and Critical Care Medicine. 21:375-384. 2000
- Aortic dissection and turner’s syndrome: case report and review of the literature. Journal of Emergency Medicine. 16:593-596. 1998
- 2 ‐Chloro‐deoxyadenosine therapy for giant lymph node hyperplasia. British Journal of Haematology. 91:668-670. 1995
- Genetic Counselling Referral Rates and Uptake of BRCA1 and BRCA2 Testing among Women Diagnosed with Serous Ovarian Cancer in a Tertiary Care Cancer Centre. Genetic Syndromes and Gene Therapy. 04.
other